Evotec slumps as Halozyme withdraws buyout offer
** Evotec's EVTG.DE shares drop around 16% in volume spike
after biotech company Halozyme HALO.O said it withdrew its
offer to acquire the German drug development company
** If losses hold Evotec's shares will see their worst day
since July; about 1.5 million shares changed hands so far today,
around 63% of their 30-day moving average full-day volume
** The stock falls to the bottom of Germany's small-cap
index .SDAXI
(Reporting by Tristan Veyet)
((Tristan.chabba@thomsonreuters.com))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases